Table of contents

Poster session

• PO.1.1 Afimetoran, a potent and selective inhibitor of human toll-like receptor 7 (TLR7) and tlr8, provides robust efficacy in a murine lupus model of advanced disease (27 September, 2022)

  S Dudhgaonkar, A Rudra, S Ranade, S Subramani, J Nagar, P Karunanithi, P Bhutani, V Kurawattimath, R Zhang, H Qiu, A Dyckman, G Schieven
• PO.1.2 Bank1 has a determinant role in the presence of age-associated b cells in autoimmunity (27 September, 2022)

  G Gómez Hernández, M Morell Hita, M Alarcón Riquelme
• PO.1.3 IL-18 deficiency does not affect development of renal tertiary lymphoid structures in imiquimod induced SLE (27 September, 2022)

  TE Olsen, AK Hovd, P Kanapathippillai, A Ursvik, C Lemoin, S Figenschau, HL Pedersen, K Fenton
• PO.1.4 The eIF4 translational inhibitor pateamine a improves immunological and neurological functions in BXSB.Yaa lupus mice (27 September, 2022)

  G Gómez-Hernández, N Varela, H Bagavant, G Barturen, M Alracón-Riquelme, M Morell
• PO.1.5 Scoring personalized molecular portraits identify systemic lupus erythematosus subtypesand predict transcriptional drug responses, symptomatology and disease progression (27 September, 2022)

  D Toro Dominguez, M Martínez Bueno, R López Domínguez, J Martorell Marugan, E Carnero Montoro, G Barturen, D Goldman, M Petri, P Carmona Saez, M Alarcón-Riquelme
• PO.1.6 Investigating monocyte transcriptomics and targeted proteomics signatures in SLE with atherosclerosis uncovers heterogeneity in inflammatory profiles (27 September, 2022)

  L Woodridge, E Chocano Navarro, P Ashford, G Robinson, K Waddington, A Rahman, C Orengo, L Jury, I Pineda-Torra
• PO.1.7 Urinary metabolomic profile of systemic lupus erythematosus and lupus nephritis based on liquid and gas chromatography/mass spectrometry (LC-QTOF-MS and GC-QTOF-MS) (27 September, 2022)

  A Rojo Sánchez, A Carmona Marte, M Santamaría Torres, Y Díaz Olmos, G Aroca Martínez, E Navarro Quiroz, M Cala Molina, L Pacheco Lugo
• PO.1.8 Distinct transcriptomic signature of peripheral blood in neuropsychiatric lupus (27 September, 2022)

  D Nikolopoulos, A Filia, K Katsiki, T Manolakou, A Pieta, N Kapsala, G Bertsias, A Fanouriakis, D Boumpas
• PO.1.9 Serum sphingolipids as a potential biomarker in patients with systemic lupus erythematosus (27 September, 2022)

  JW Kim, CH Suh, SH Kim, SJ Hong
• PO.1.10 Multicentre study in sle patients with and without renal involvement by label free proteomic analysis of 24h urine (27 September, 2022)

  N Rivera, E Ruiz, J Calvo, E Aurrecoechea, L Riancho, A De Diego-Sola, M Diaz, E Galindez, O Fernandez, I Torre, E Cuende, J Blanco, A Intxaurbe, R Exposito, C Garcia, L Vega, M Enjuanes, M Allande, F Elortza, I Iloro, M Azkargorta, M García-Vivar
• PO.1.12 Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus (27 September, 2022)

  J Lindblom, D Toro-Domínguez, E Carnero-Montoro, MO Borghi, J Castillo, E Iacobaeus, Y Enman, D Repsilber, C Mohan, M Alarcón-Riquelme, G Barturen, I Parodis
• PO.1.13 Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus (27 September, 2022)

  KA Zervides, S Janelidze, J Nystedt, B Gullstrand, P Nilsson, PC Sundgren, AA Bengtsson, O Hansson, A Jönsen
• PO.1.14 Evaluation of cognitive impairment in SLE – a comparison of two assessment tools (27 September, 2022)

  E Fazekas, G Bodor, S Burcsár, R Hemelein, J Kálmán, B Rafael, L Kovács
• PO.1.15 Lupus brain fog: cognitive impairment and depression in systemic lupus erythematosus (27 September, 2022)

  S Fasano, M Patrone, F Riccio, A Milone, L Sadile, M Fabrazzo, E Di Caprio, R Tirri, F Ciccia
• PO.1.16 Limbic encephalitis: a rare complication of systemic lupus erythematosus (27 September, 2022)

  T Asmaa, A Wafa, W Chawad, F Ibourk El Idrissi, H Harmouche, M Maamar, H Khibri, Z Tazi Mezalek, M Adnaoui
• PO.1.19 Lupus vasculitis manifesting as eight-and-a-half syndrome (27 September, 2022)

  Marina Barguil Macêdo, Jean Michell Correia Monteiro, Pablo Vinícius da Fonseca, Diogo Souza Domiciano, Samuel Katsuyuki Shinjo
• PO.1.20 Prognostic biomarkers of organ damage in patients with newly diagnosed SLE (27 September, 2022)

  H Enocsson, A Jönsen, AA Bengtsson, M Eloranta, E Svenungsson, I Gunnarsson, L Rönnblom, D Leonard, C Sjöwall
• PO.1.21 Attainment of EQ-5D-3L full health state after therapy is associated with decelerated organ damage accrual in systemic lupus erythematosus (27 September, 2022)

  J Lindblom, S Zetterberg, A Borg, S Emamikia, G Von Perner, Y Enman, E Heintz, M Regardt, D Grannas, A Gomez, I Parodis
• PO.1.22 Online education significantly improved rheumatologists’ knowledge and confidence in minimizing long-term organ damage in SLE (27 September, 2022)

  E Bell, M Calle, R Van Vollenhoven
• PO.1.23 Thrombocytopenia as a predictor of systemic lupus erythematosus progression (27 September, 2022)

  M Osipyan, M Efremidou, K Ginosyan
• PO.1.24 Avascular necrosis of bone in a patient with systemic lupus erythematosus without corticosteroid use: a case report (27 September, 2022)

  J Noh, S Han
• PO.1.26 Connective tissue systemic diseases and its oral health implications (27 September, 2022)

  B Przywara-Chowaniec, A Puzio, D Blachut, L Postek-Stefanska, B Morawiec
• PO.2.27 Early changes in the circulating B cell compartment associated with response to treatment and occurrence of flares in patients receiving therapy for active systemic lupus erythematosus (27 September, 2022)

  M Gatto, A Gomez Gonzales, J Lindblom, A Doria, I Parodis
• PO.2.28 Intracellular oxidative stress in t-cells is associated with the disease activity of lupus (27 September, 2022)

  A Tandon, A Sharma, A Bhatnagar
• PO.2.29 Serum levels of b-cell related factors belonging to the tnf/tnfr superfamily are lower in antiphospholipid-related syndromes than in systemic lupus erythematosus (27 September, 2022)

  S Piantoni, F Regola, T Lowin, S Bertocchi, E Pedretti, S Tamanini, A Tincani, F Franceschini, L Andreoli, G Pongratz
• PO.2.30 IGG/IGM autoantibody ratios do not relate to progression from incomplete systemic lupus erythematosus to systemic lupus erythematosus (27 September, 2022)

  S Henning, J Westra, V Nedomova, B Horvath, H Bootsma, K De Leeuw
• PO.2.31 Different patterns of longitudinal changes in antinuclear antibodies titres in children with systemic lupus erythematosus (27 September, 2022)

  P Morán Álvarez, C Bracaglia, V Messia, I Caiello, F De Benedetti, E Marasco
• PO.2.32 Disease activity correlation of anti-dsdna, anti-sm and anti-ribo-p autoantibodies in systemic lupus erythematosus using the novel pmat technology (27 September, 2022)

  A Seaman, C Andalucia, A Pérez-Isidro, E Ruiz-Ortiz, J Ballús, R Ríos-Garcés, R Cervera, MA Aure, O Viñas, M Mahler
• PO.2.33 Association of ACPA and RF antibodies with synovitis and joint destruction in algerian patients with rhupus (27 September, 2022)

  S Louahchi, N Khaldoun, L Boulgheb, R Djidjik, A Galleze, R Raache, F Hanni, C Touil-Boukoffa
• PO.2.34 Anti-DNase i antibodies: an emerging diagnostic marker of SLE (27 September, 2022)

  A Trofimenko, M Mamus, E Mozgovaya, S Bedina, S Spitsina
• PO.2.35 Association between clinical manifestations and SLE-specific antibodies measured by a novel pmat technology in systemic lupus erythematosus (27 September, 2022)

  A Seaman, C Andalucia, M López-Hoyos, J Irure-Ventura, E González-López, A Roa-Bautista, E Aron, MA Aure, M Mahler
• PO.2.36 Characterization of peripheral blood b-cell subset in untreated patients with systemic lupus erythematosus (27 September, 2022)

  E Gerasimova, D Tabakov, T Popkova, A Avdeeva
• PO.2.37 Risk factors for recurrent thrombosis and cause of death in patients with antiphospholipid syndrome; a Swedish cohort study (27 September, 2022)

  N Karandyszowska, H Alagündüz, J Oesman, M Magnusson, E Svenungsson, M Bruzelius, A Antovic
• PO.2.38 Anti-β2GPI-domain 1 antibodies stratify high risk of extra-criteria manifestations in a large prospective chinese cohort of antiphospholipid syndrome (27 September, 2022)

  Y Zhou, W Qi, J Zhao, M Li, X Zeng
• PO.2.39 Long term follow up of patients with primary obstetric antiphospholipid syndrome (27 September, 2022)

  S Niznik, M Rapoport, O Avnery, M Ellis, A Lubetsky, R Shavit, N Agmon-Levin
• PO.2.40 High expression of CD11c+Tbet+ B cell in triple APL positive primary obstetric antiphospholipid syndrome patients (27 September, 2022)

  Y Long, J Zhao, X Tian, M Li, X Zeng
• PO.2.41 Clinical characteristics of adverse pregnancy outcome patients with APL-positive in chinese cohort (27 September, 2022)

  Y Long, J Zhao, X Tian, M Li, X Zeng
• PO.2.42 The value of IGA-ACL and IGA-AB2-GP1 in clinical and laboratory manifestations of systemic lupus erythematosus (27 September, 2022)

  F Cheldieva, A Shumilova, T Reshetnyak, M Cherkasova, A Lila
• PO.2.43 The activity and damage index in systemic lupus erythematosus depending on antiphospholipid antibodies (27 September, 2022)

  A Shumilova, F Cheldieva, T Reshetnyak, M Cherkasova, A Lila
• PO.2.44 Catastrophic anti-phospholipid syndrome and peripartum: a new observation! (27 September, 2022)

  N Bouziani, A Kella, A Belabbas, K Bouadjadj, D Hakem
• PO.2.45 Autoantibodies associated with systemic sclerosis (SSC) in three diseases characterized by type I interferons: a comparison between SLE, primary Sjögren’s syndrome, SSC and healthy blood donors (27 September, 2022)

  R Andraos, A Ahmad, P Eriksson, Ö Dahlström, L Wirestam, C Dahle, R Hesselstrand, K Andréasson, C Sjöwall
• PO.2.46 Clinical and immunological considerations of ceruloplasmin activity shifts in systemic lupus erythematosus (27 September, 2022)

  A Trofimenko, O Emelyanova
• PO.2.47 How small details affect the sensitivity of different SLE criteria? Investigating a large number of patients in a Hungarian center (27 September, 2022)

  DL Csóka, K Tkovács, L Czirják, G Kumánovics
• PO.2.48 Incomplete systemic lupus erythematosus: clinical and immunological manifestations (27 September, 2022)

  T Panafidina, T Popkova, L Kondrateva, Y Gorbunova, E Nasonov, A Lila
• PO.2.49 Predictors of progression in undifferentiated connective tissue disease: a systematic review and meta-analysis (27 September, 2022)

  S Dyball, M Rodziewicz, C Mendoza-Pinto, B Parker, IN Bruce
• PO.2.50 Utility in clinical practice of anti-dsdna autoantibodies vs antidna crithidia luciliae in the diagnosis of systemic lupus erythematosus (27 September, 2022)

  V Ortiz-Santamaria, A Nack, J Climent-Martí, À Prior-Español, L Mateo Soria, M Martínez-Morillo, L Gifre, M Aparicio-Espinar, A Riveros, C Sangüesa, J Camins-Fàbregas, I Casafont-Solé, M Aparicio-Rovira, I Peralta-Garcia, S Holgado
• PO.2.51 Hyperferritinaemia and systemic disease : SLE or still’s disease? (27 September, 2022)

  A Kella, N Bouziani, A Belabbas, A Khedim, D Hakem
• PO.3.52 Predictors of cardiovascular events in systemic lupus erythematosus (27 September, 2022)

  N Farina, J Webster, W Luo, D Isenberg, A Rahman
• PO.3.53 No evidence of a correlation between serum HCQ concentrations and QTc in SLE (27 September, 2022)

  A Olsson, H Tydén, K Kultima, H Carlsson, P Linge, AA Bengtsson, A Jönsen
• PO.3.54 Association of lupus nephritis and echocardiographic parameters (27 September, 2022)

  N Guajardo-Jauregui, DA Galarza-Delgado, IJ Colunga-Pedraza, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
• PO.3.55 Estimation of cardiovascular risk among SLE patients: analysis from a monocentric cohort (27 September, 2022)

  R Santangeli, G Montozzi, L Gamba, S Salvucci, L Manfredi, G Moroncini
• PO.3.56 Anti- Ro/SSA antibodies and electrocardiographic abnormalities in SLE patients: preliminary data of a multidisciplinary study in a monocentric cohort (27 September, 2022)

  S Bertocchi, E Pedretti, R Rovelli, L Serafini, A Drera, M Riccardi, F Ravasio, E Vizzardi, F Franceschini, M Fredi
• PO.3.57 Correlation between disease activity and echocardiographic parameters in systemic lupus erythematosus patients (27 September, 2022)

  N Guajardo-Jauregui, DA Galarza-Delgado, IJ Colunga-Pedraza, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
• PO.3.58 Association of anti-double stranded dna antibody titers and echocardiographic parameters in systemic lupus erythematosus patients (27 September, 2022)

  N Guajardo-Jauregui, IJ Colunga-Pedraza, DA Galarza-Delgado, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
• PO.3.59 Echocardiographic abnormalities in systemic lupus erythematosus patients (27 September, 2022)

  N Guajardo-Jauregui, IJ Colunga-Pedraza, DA Galarza-Delgado, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
• PO.3.60 Association of left ventricular geometry abnormalities and disease activity in systemic lupus erythematosus patients (27 September, 2022)

  N Guajardo-Jauregui, JR Azpiri-Lopez, DA Galarza-Delgado, IJ Colunga-Pedraza, JA Cardenas-De La Garza, S Lugo-Perez
• PO.3.61 Renal involvement and cardiovascular risk in systemic lupus erythematosus patients (27 September, 2022)

  M De La Rubia Navarro, E Grau Garcia, C Pavez Perales, JR Ivorra Cortes, L Gonzalez Puig, R Negueroles Albuixech, I Martinez Cordellat, C Herranz Najera, OS Francisco Miguel, J Fragio Gil, I Canovas Olmos, E Vicens Bernabeu, JE Oller Rodriguez, S Leal Rodriguez, C Riesco Barcena, AV Huaylla Quispe, L Mas Sanchez, P Muñoz Martinez, JA Roman Ivorra
• PO.3.62 Cardiopulmonary disease in SLE- increasing trend! (27 September, 2022)

  S Balasubramanian, S Nallasivan
• PO.3.64 Optimising type I interferon gene expression assays: addressing the research agenda of a eular task force (27 September, 2022)

  Z Wigston, L Carter, A Alase, E Vital
• PO.3.65 The leptin and adiponectin levels in patients with systemic lupus erythematosus and their relationship with cardiovascular risk factors (27 September, 2022)

  L Kondrateva, Y Gorbunova, M Diatroptov, T Popkova, T Panafidina, E Gerasimova
• PO.3.66 TLR9 protein level is associated to proinflammatory cytokine level of IL10 and inf1a in SLE patients (27 September, 2022)

  E Grau García, L Gomez-Lechón Quirós, C Riesco Barcena, AV Huaylla Quispe, S Leal Rodríguez, C Pávez Perales, L Mas Sanchez, P Muñoz Martínez, M De La Rubia Navarro, I Cánovas Olmos, J Ivorra Cortés, JJ Fragio Gil, L González Puig, I Martínez Cordellat, C Nájera Herranz, R Negueroles Albuixech, JE Oller Rodríguez, FM Ortiz-Sanjuán, E Vicens Bernabéu, JA Roman Ivorra
• PO.3.67 Measuring IFNA2 levels by a single-molecule array in clinical practice of childhood-onset sle patients does matter; results from a single center longitudinal study (27 September, 2022)

  Marleen Verkaaik, Wahadat M Javad, Hongchao Qi, Cornelia G van Helden-Meeuwsen, Erika Huijser, Lotte van den Berg, Jens Göpfert, Marleen Verkaaik, Marco Schreurs, Sylvia Kamphuis, Marjan A Versnel
• PO.3.68 Systemic lupus erythematosus-related intestinal pseudo-obstruction treated with immunosuppressants (27 September, 2022)

  L Mustafayeva, I Durucan, AY Ayla, S Ugurlu
• PO.3.69 A case of late onset of primary antiphospholipid syndrome (27 September, 2022)

  S Salvucci, L Manfredi, L Gamba, G Montozzi, R Santangeli, G Moroncini
• PO.3.70 Case report of a systemic lupus erythematosus patient with an ulcerative necrotic vasculitis: features of therapeutic approaches (27 September, 2022)

  A Shumilova, E Naryshkin, E Stolyarevich, T Reshetnyak
• PO.3.71 A unique case of a delayed diagnosis of strongyloidiasis hyperinfection in a patient with systemic lupus erythematosus, lymphoplasmacytic lymphoma, and kidney injury (27 September, 2022)

  D Bosnic, I Aurer, S Bulimbašic
• PO.3.72 Extracellular vesicles opsonized by monomeric C-reactive protein are accessible as autoantigens in systemic lupus erythematosus (27 September, 2022)

  J Karlsson, J Wetterö, L Potempa, F Mobarrez, C Sjöwall
• PO.3.73 Soluble CD200 concentration in serum is increased in SLE patients and correlates with anti-dsdna (27 September, 2022)

  E Kaan, M Limper, M Van Der Vlist
• PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash (27 September, 2022)

  RF Van Vollenhoven, RA Furie, K Kalunian, VP Werth, H Carroll, X Huang, C Musselli, C Barbey, N Franchimont
• PO.4.77 Agreement between lldas and expert assessment in identifying SLE patients with LDA: study on a real-world cohort of caucasian patients (27 September, 2022)

  C Cruciani, M Zen, F Arru, F Davanzo, Z Rahmé, R Depascale, M Gasparotto, M Gatto, L Iaccarino, A Doria
• PO.4.78 Validation analysis of the physician global assessment (PGA) scale in patients with systemic lupus erythematosus included in relesser-pros registry (27 September, 2022)

  L Cáceres, I Rúa-Figueroa Fernández De Larrrinoa, N Jiménez, M Galindo Izquierdo, J Calvo Alen, R Menor Almagro, A Fernández Nebro, J Martínez Barrios, JM Pego Reigosa
• PO.4.79 Nailfold capillary changes in patients with systemic lupus erythematous (27 September, 2022)

  S Stefania, C Rotondo, S Sciacca, FP Cantatore, A Corrado
• PO.4.80 Significant correlation between adjusted mean clinical sledai over time and remission defined by the doris criteria: results from a regional Swedish cohort (27 September, 2022)

  I Giannakou, M Frodlund, L Rönnblom, C Sjöwall, D Leonard
• PO.4.81 Variability of xanthine oxidoreductase activity patterns in systemic lupus erythematosus and rheumatoid arthritis (27 September, 2022)

  A Trofimenko, E Mozgovaya, S Bedina, M Mamus, S Spitsina, I Zborovskaya
• PO.4.82 Correlation between anti ds-dna and systemic lupus erythematosus disease activity (27 September, 2022)

  N Ajasllari, M Uruci, A Zoto, E Rapushi, J Petromilo
• PO.4.83 Anemia as an obtainable marker of systematic lupus erythematosus activity assessment (27 September, 2022)

  M Osipyan, M Efremidou, K Ginosyan
• PO.4.84 Infections in infants born to mothers with systemic lupus erythematosus and the role of preterm birth (27 September, 2022)

  S Gernaat, J Simard, E Svenungsson, E Arkema
• PO.4.85 What are the sex differences in patients with systemic lupus erythematosus? (27 September, 2022)

  T Panafidina, T Popkova, E Gerasimova, Y Gorbunova
• PO.4.86 Cluster analysis of initial laboratory findings identifies three clinical clusters in patients with systemic lupus erythematosus (27 September, 2022)

  C-H Suh, J-Y Jung, S-S Kim, S-H Lee
• PO.4.87 Racial discrimination and telomere shortening: findings from the black women’s experiences living with lupus (BeWELL) study (27 September, 2022)

  DH Chae, CD Martz, KW Chung, DJ Cunningham, AM Allen, TA Laveist, KG Saag, MI Danila
• PO.4.89 Hashimoto’s thyroiditis in systemic lupus erythematosus patients (27 September, 2022)

  P Athanassiou, L Athanassiou, M Mavroudi, P Tsakiridis, N Koukosias, I Kostoglou-Athanassiou
• PO.4.90 Remission and clinical patterns of systemic lupus erythematosus (SLE) in southern pakistan: a retrospective cohort study (27 September, 2022)

  Mohammad Saeed, Aneela Pasha, Syed Hussain Azhar Rizvi, Maham Munawar, Zehra Abaad Elias, Muhammad Irfan Shafi, Tario Gazdar, Maryam Pyar Ali Lakhdir
• PO.4.91 Bank1 and IL-10+ B cells: bringing some light to the relationship between microbiota composition and autoimmunity development in a murine model of lupus (27 September, 2022)

  M Botía-Sánchez, G Galicia, D Toro-Domínguez, L Albaladejo-Maricó, ME Alarcón-Riquelme
• PO.4.92 Taxonomy, treatment, targets and remission in systemic lupus erythematosus: the 3TR-SLE study protocol (27 September, 2022)

  I Parodis, AE Voskuyl, ME Alarcón-Riquelme, L Beretta
• PO.4.94 High B-cell polygenic risk is associated with dsDNA antibodies and nephritis in systemic lupus erythematosus (27 September, 2022)

  A Hedenstedt, S Reid, A Sayadi, M Eloranta, E Skoglund, K Bolin, M Frodlund, K Lerang, A Jönsen, S Rantapää-Dahlqvist, A Bengtsson, A Rudin, Ø Molberg, C Sjöwall, L Rönnblom, J Sandling, D Leonard
• PO.4.95 Cluster-based genome-wide association meta-analysis in european and Chinese datasets for systemic lupus erythematosus (27 September, 2022)

  M Saeed
• PO.4.96 The epigenome of systemic lupus erythematosus: molecular subtypes, autoantibody profiles, and genetic influences (27 September, 2022)

  E Carnero-Montoro, O Castellini-Pérez, G Barturen, G Martínez-Bueno, M Kerick, A Iakovliev, R López-Dominguez, J Martin, A Spiliopoulou, E Derinaldis, ME Alarcón-Riquelme
• PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis (27 September, 2022)

  C Lindholm, HI Brunner, E Cody, P Devarajan, B Huang, D Sinibaldi, M Ramaswamy, J Knagenhjelm, T Qiu, F Jones, PZ Brohawn, R Tummala, WI White
• PO.5.98 Glomerular activity at second kidney biopsy predicts of end-stage kidney disease in a large multi-centric cohort of patients with active lupus nephritis (27 September, 2022)

  M Gasparotto, M Gatto, RA Sinico, G Moroni, L Iaccarino, A Doria
• PO.5.99 Drug repurposing for treating lupus nephritis based on transcriptome profiling and autoimmunity-related serological markers (27 September, 2022)

  I Parodis, J Lindblom, D Toro-Domínguez, E Carnero-Montoro, MO Borghi, J Castillo, Y Enman, D Repsilber, C Mohan, M Alarcón-Riquelme, G Barturen
• PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis (27 September, 2022)

  L Andreoli, Z Amoura, E Morales, A Jones-Leone, RA Levy, JA Gilbride, H Carnarius, P Korsten
• PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification (27 September, 2022)

  I Parodis, L Liefaard, Y Green, JA Gilbride, C Henning, RA Levy, R Dimelow
• PO.5.103 Study of b cells in patients with lupus nephritis: parameters of disease activity and remission (27 September, 2022)

  C Di Mario, V Varriano, L Petricca, AM Paglionico, MR Gigante, S Alivernini, B Tolusso, E Gremese
• PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE (27 September, 2022)

  S Jägerback, A Gomez, I Parodis
• PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis (27 September, 2022)

  J Weinmann-Menke, M Okada, C Arriens, A Jones-Leone, RA Levy, JA Gilbride, R Furie, N Yang
• PO.5.107 Real-world clinical response of tacrolimus treatment in patients with lupus nephritis (27 September, 2022)

  C Suh, J Kim, S-J Hong, S-H Lee
• PO.5.108 Combined model of renal histopathology and clinical parameters better predicts one-year renal outcomes in lupus nephritis: analysis of 334 kidney biopsies (27 September, 2022)

  A Gopal, C Kavadichanda, D Bairwa, S Shah, S Bh, S Mehra, M Thabah, V Negi
• PO.5.110 Plasma levels of osteopontin in SLE (27 September, 2022)

  M Compagno, B Gullstrand, C Lood, A Jönsen, C Sjöwall, A Bengtsson
• PO.5.111 Long-term follow-up of plasma-free thiols levels in patients with lupus nephritis (27 September, 2022)

  L Liu, K De Leeuw, S Arends, B Doornbos-Van Der Meer, H Van Goor, J Westra
• PO.5.112 Diffuse alveolar hemorrhage in lupus nephritis patients: a multicenter retrospective study (27 September, 2022)

  R Ahmed, S Abdulaziz, H Halabi, S Bahlas, S Attar, M El Dessougi, A Alhouri, A Altaroti, H Alrayes, A Albaity, H Fida
• PO.5.113 C3 and C1Q deposition in different kidney compartments is not associated with serious infections in lupus nephritis (27 September, 2022)

  T Knezevic, I Padjen, V Ivkovic, M Laganovic, I Jezic, Z Biloglav, S Bulimbasic, M Coric, M Mayer, B Anic
• PO.5.114 Online education significantly improved rheumatologists’ knowledge of the burden of lupus nephritis and appropriate treatment strategies for patients (27 September, 2022)

  E Bell, M Calle, L Lightstone
• PO.5.115 Systemic lupus erythematosus (SLE): patients with and without renal involvement: a real world analysis showing demographic, clinical and treatment differences across more than 1,279 EU5 patients (27 September, 2022)

  M Yarnall, R Rex, P Pouliot
• PO.5.116 Lupus nephritis response in terms of kidney function, urine sediment and serological activity after belimumab treatment (27 September, 2022)

  M De La Rubia Navarro, E Grau Garcia, C Pavez Perales, S Leal Rodriguez, C Riesco Barcena, AV Huaylla Quispe, JR Ivorra Cortes, L Gonzalez Puig, R Negueroles Albuixech, I Martinez Cordellat, C Najera Herranz, J Fragio Gil, R Gonzalez Mazario, I Canovas Olmos, E Vicens Bernabeu, J Oller Rodriguez, L Mas Sanchez, P Muñoz Martinez, JA Roman Ivorra
• PO.5.117 Serum atherogenicity in women with untreatedlupusnephritis (27 September, 2022)

  EV Gerasimova, TV Popkova, TV Kirichenko, DA Gerasimova
• PO.5.118 Functional multiparametric mri to assess renal involvement in SLE (27 September, 2022)

  I Haase, A Kernder, A Ljimani, G Chehab, J Mucke, C Düsing, R Fischer-Betz, P Sewerin, O Sander, G Antoch, M Schneider
• PO.6.119 Low-dose belimumab and antimalarial agents prevent renal flares in systemic lupus erythematosus: results from four randomised clinical trials (27 September, 2022)

  A Gomez, S Jägerback, C Sjöwall, I Parodis
• PO.6.120 Non-pharmacological management of systemic lupus erythematosus and systemic sclerosis: a systematic literature review to inform eular recommendations (27 September, 2022)

  I Parodis, A Gomez, A Tsoi, JW Chow, D Pezzella, C Girard, T Stamm, C Boström
• PO.6.121 Epistemic injustice and educational needs for self-management in systemic lupus erythematosus (27 September, 2022)

  YJ Fuentes-Silva, M Solé, C Acosta, WM Bermúdez Marrero, C Elera-Fitzcarrald, S Ibañez, C Reátegui-Sokolova, A Vanegas, B Pons-Estel, C Drenkard
• PO.6.123 A rapid decalage of immunosuppressive therapy in a young woman with systemic lupus erythematosus (27 September, 2022)

  G Montozzi, L Gamba, R Santangeli, S Salvucci, L Manfredi, G Moroncini
• PO.6.124 Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus (27 September, 2022)

  M Okada, S Fukui, Y Ikeda, A Nomura, H Tamaki, M Kishimoto, T Nakai
• PO.6.125 To have butterflies in one’s . . . medical report! (27 September, 2022)

  S Huot, PR Fortin, AS Julien, M Pouliot
• PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus (27 September, 2022)

  C Wincup, N Dunn, C Ruetsch-Chelli, A Manouchehrinia, N Kharlamova, M Naja, B Seitz-Polski, D Isenberg, A Fogdell-Hahn, C Ciurtin, E Jury
• PO.6.127 Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory t cells in patients with SLE: final results of a phase 1b multiple ascending dose study (27 September, 2022)

  N Tchao, N Sarkar, X Hu, R Zhang, C Milmont, Y Shi Jin, V Chow, M Kroenke, K Gorski, R Furie, K Alan, C Stanley
• PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry (27 September, 2022)

  T Walhelm, L Wirestam, I Parodis, C Sjöwall
• PO.6.129 Antimalarial therapy and its discontinuation in clinical practice: data from a large Italian cohort (27 September, 2022)

  E Fuzzi, M Zen, R Depascale, A Doria
• PO.6.130 Rapid efficacy of anifrolumab in multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels discrete changes in transcriptomic and cellular biomarkers (27 September, 2022)

  LM Carter, Z Wigston, P Laws, EM Vital
• PO.6.131 A randomized, double-blind, placebo controlled study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-303, a potent dual baff/april inhibitor, in adult healthy volunteers (27 September, 2022)

  P Harrison, J Lickliter, S Dillon, K Manjarrez, A Smith, M Lessig, R Sanderson, A Chunyk, H Zayed, S Peng
• PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design (27 September, 2022)

  U Ranganathan, JT Merrill, MK Crow, N Delev, S Banerjee, D Grasela, M Harrison, Y Shen, E Culotta, S Greenberg, V Shah
• PO.6.133 Dynamical trajectory of glucocorticoid tapering and discontinuation in real-world patients with newly diagnosed systemic lupus erythematosus: the gulp study (27 September, 2022)

  M Piga, E Chessa, A Floris, GD Sebastiani, I Prevete, F Iannone, L Coladonato, M Govoni, A Bortoluzzi, M Mosca, C Tani, A Doria, L Iaccarino, F Franceschini, M Fredi, F Conti, FR Spinelli, F Bellisai, R D’Alessandro, A Zanetti, G Carrara, CA Scirè, A Cauli
• PO.6.134 Safety and tolerability of nipocalimab administered at different rates of intravenous infusion in healthy adults: a phase 1 placebo-controlled single-dose study (27 September, 2022)

  J Leu, A Vermeulen, F Zazzetti, L Ling
• PO.6.135 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW) (27 September, 2022)

  EF Morand, VP Werth, A Bender, A Deshpande, A Deshmukh, B Vaidyanathan, C Vazquez-Mateo, M Przetak, F Moreau, M Khursheed, S Roy, DR Pearson
• PO.6.136 Systemic lupus erythematosus (SLE): a real world analysis showing significant variance in treatment patterns among 1,279 systemic lupus erythematosus (SLE) patients in the EU5 (27 September, 2022)

  Y Maxine, R Ryan
• PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active systemic lupus erythematosus (27 September, 2022)

  F Liu-Walsh, B Van Hartingsveldt, Q Zuraw, RW Hoffman, T Rooney, S Gao, R Gordon, JH Leu, A Berhanu Debella, C Calderon, F Zazzetti, G Vratsanos
• PO.6.139 Effect and safety profile of belimumab and tacrolimus (B-T) combination therapy in 33 patients with systemic lupus erythematosus: a single-center retrospective analysis (27 September, 2022)

  T Nakai, S Fukui, G Kidoguchi, Y Ikeda, A Kitada, A Nomura, H Tamaki, M Kishimoto, M Okada
• PO.6.140 Treatment pattern of patients with systemic lupus erythematosus: a cohort study at rheumatologist practices in germany (27 September, 2022)

  J Montonen, S De Souza, C Foch, C Vazquez-Mateo, S Roy, T Dörner
• PO.6.141 Efficacy of mycophenolate mofetil (MMF) in pediatric patients with defined and undefined type I interferonopathies (27 September, 2022)

  MF Natale, C Udina, CGL Raffaele, V Messia, C Celani, C Bracaglia, S Federici, G Prencipe, F De Benedetti, A Insalaco
• PO.7.142 Health-related quality of life across the spectrum of connective tissue diseases: a latent profile analysis (27 September, 2022)

  S Dyball, J Reynolds, IN Bruce, B Parker
• PO.7.143 Value of fatigue: patients vs. Physicians – time trade-off approach results from a patient survey (27 September, 2022)

  C Duesing, M Schneider, G Chehab
• PO.7.144 ASSESSLE- a new tool to assess sle disease activity- the patients’ perspective (27 September, 2022)

  D Paran, M Ben-Am, L Mendel, P Ari, V Furer, O Elalouf, J Wollman, T Eviatar, S Pel, S Kivity, O Elkayam, N Agmon-Levin
• PO.7.145 Active skin involvement in patients with systemic lupus erythematosus: analysis of the impact on health-related quality of life and patient perception of health status (27 September, 2022)

  E Elefante, V Signorini, C Stagnaro, D Zucchi, F Trentin, I Salvi, C Lazzareschi, L Carli, F Ferro, C Tani, M Mosca
• PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus (27 September, 2022)

  N Hua, A Gomez, J Lindblom, G Von Perner, Y Enman, M Regardt, E Heintz, S Emamikia, D Grannas, I Parodis
• PO.7.147 Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in patients with systemic lupus erythematosus from a Swedish tertiary referral centre (27 September, 2022)

  A Gomez, I Parodis, C Sjöwall
• PO.7.148 Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study (27 September, 2022)

  F Ceccarelli, V Covelli, G Olivieri, F Natalucci, C Alessandri, F Conti
• PO.7.149 Associations between abnormal bmi and patient-reported health-related quality of life before and after therapeutic intervention in patients with systemic lupus erythematosus (27 September, 2022)

  A Borg, A Soltani, S Emamikia, J Lindblom, A Gomez, G Von Perner, Y Enman, E Heintz, M Regardt, D Grannas, I Parodis
• PO.7.150 Experience of daily activities among persons with systemic lupus erythematosus with cognitive symptom (27 September, 2022)

  A Sturesson Marklund, AA Bengtsson, A Jönsen
• PO.7.151 The relationship between health-related quality of life and disease activity in sle patients (27 September, 2022)

  S Salvucci, R Santangeli, G Montozzi, L Gamba, C Cocco, P Fioretti, L Manfredi, G Moroncini
• PO.7.152 Comparison of educational needs among patients with systemic lupus erythematosus and ANCA associated vasculitis – a pilot study using the educational needs assessment tool (27 September, 2022)

  S Brolin, E Svenungsson, I Gunnarsson, S Pettersson
• PO.7.153 Systemic lupus-dermatomyositis overlapping syndrome: a case report (27 September, 2022)

  N Bouziani, A Belabbas, M Derder, D Hakem
• PO.7.154 Jaccoud’s rheumatism during systemic lupus: a case report (27 September, 2022)

  A Kella, N Bouziani, A Belabbas, M Derder, D Hakem
• PO.7.155 Study of the comorbidities present in the patients included in the registry of systemic lupus erythematosus of the spanish society of rheumatology (relesser) (27 September, 2022)

  A Lois-Iglesias, R Iñigo, M Galindo Izquierdo, J Calvo-Alén, V Balboa-Barreiro, C Mouriño, A Olivé, R Melero, A Fernández-Nebro, M Andrés, C Erausquin, E Tomero, C Fito, E Uriarte, M Freire, C Montilla, A Morasat, G Santos-Soler, A Boteanu, E León, J Narvaez, V Taboada, L Silva, O Ibarguengoitia, M Fernandez-Castro, JA Hernadez-Beirian, M Gantes, B Hernández-Cruz, J Pérez-Venegas, A Pecondon, N Lozano, AP Cacheda, G Bonilla, V Torrente-Segarra, I Castellvi, JJ Alegre, J Calvet, JL Marenco, E Raya, T Vázquez, Q Víctor, S Muñoz, T Otón, J Martínez Barrio, JM Pego-Reigosa
• PO.7.156 Does expert opinion match the definitions of low disease activity state? Prospective analysis of 500 patients from a spanish multicenter cohort (27 September, 2022)

  I Altabás González, Í Rúa-Figueroa, F Rubiño, C Mouriño, R Menor Almagro, E Uriarte Isacelaya, E Tomer Muriel, TC Salman-Monte, I Carrión-Barberà, M Galindo, E Rodríguez-Almaraz, N Jiménez, JM Pego-Reigosa
• PO.7.157 Does remission according DORIS 2021 match the treating rheumatologist judgement? Analylis at recruitment of a prospective study of 500 SLE patients from a Spanish multicenter cohort (27 September, 2022)

  I Altabás González, Í Rúa-Figueroa, F Rubiño Juarez, C Mouriño, I Hernández, R Almagro, E Uriarte Isacelaya, E Tomero Muriel, T Salman, I Carrión-Barberà, M Galindo, M Rodríguez Almaraz, N Jiménez, L Inês, JM Pego-Reigosa
• PO.7.158 Lupusnet – a federated model/network to support real-world data research in systemic lupus erythematosus (27 September, 2022)

  J Schreiber, M Van Speybroeck, W Noël, TA Simon, F Lavie
• PO.7.159 Objective measures of health-related quality of life may not adequately reflect diseaseburden in systemic lupus erythematosus (27 September, 2022)

  M Björk, T Stephens, A Dominicus, D Eek, C Sjöwall
• PO.7.160 Enlight-LN: a prospective observational registry of patients treated with voclosporin for lupus nephritis in the united states (27 September, 2022)

  N Slawny, A Pavlova-Wolf, C Collins, R Gluck, L Hodge, H Leher
• PO.7.161 Clinical and immunological characterization of systemic lupus erythematosus (SLE) patients in estonia. A prospective cohort study of 40 SLE patients in estonia (27 September, 2022)

  S Meisalu, K Kisand
• PO.7.162 Epidemiology of systemic lupus erythematosus in central Sweden: a population-based cohort study from the östergötland county over 14 years (27 September, 2022)

  EV Arkema, M Saleh, JF Simard, C Sjöwall
• PO.7.163 Epidemiology of systemic lupus erythematosus among black africans living in Africa: a pooled analysis of data from 896 subjects (27 September, 2022)

  M Essouma, JR Nkeck, FT Endomba, JJ Bigna, M Singwe-Ngandeu, E Hachulla
• PO.8.164 Melanoderma induced by long-term use of hydoxychloroquine in SLE (27 September, 2022)

  A Kella, F Derbal, N Bouziani, A Belabbas, M Derder, D Hakem
• PO.8.165 Whole-blood dna methylation analysis reveals respiratory environmental traits involved in COVID-19 severity following SARS-CoV-2 infection (27 September, 2022)

  G Barturen, E Carnero-Montoro, M Martínez-Bueno, S Rojo-Rello, B Sobrino, C Alcántara-Domínguez, D Bernardo, ME Alarcón-Riquelme
• PO.8.167 Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus (27 September, 2022)

  F El Hadiyen, M Tsang-A-Sjoe, B Lissenberg-Witte, A Voskuijl, I Bultink
• PO.8.168 The third dose of mRNA COVID 19 vaccine is safe and efficacious for SLE patients receiving belimumab (27 September, 2022)

  Y Tunitsky-Lifshitz, R Maoz-Segal, M Iancovici-Kidon, S Niznik, R Shavit, S Haj Yahia, N Agmon-Levin
• PO.8.169 Immune responses to mrna vaccines against SARS-COV-2 in patients with immune-mediated inflammatory rheumatic diseases (27 September, 2022)

  C Sieiro Santos, C Moriano Morales, E Díez Alvarez
• PO.8.170 Drug-induced lupus or systemic lupus erythematosus after experimental COVID-19 therapy: difficulties in differential diagnosis (27 September, 2022)

  M Aristova, T Panafidina, T Popkova, Y Gorbunova, A Misiyuk, M Kurbanmagomedov
• PO.8.171 Changes in follow-up activities in SLE patients during the COVID-19 pandemic and its impact on health outcomes (27 September, 2022)

  S Snoeck Henkemans, AE Berden, G Waverijn, I Verberk, MR Kok, EJM Zirkzee
• PO.8.172 Disease activity at the time of biopsy is not associated with higher risk of serious infections in patients with lupus nephritis (27 September, 2022)

  T Kneževic, I Padjen, V Ivkovic, M Laganovic, I Ježic, Z Biloglav, S Bulimbašic, M Coric, M Mayer, B Anic
• PO.8.173 Lupus nephritis and COVID 19 : a case report (27 September, 2022)

  H Mimoune, L Benchoufi, Y Kitouni
• PO.8.174 A lupus patient with acute renal vein thrombosis following COVID- 19 (27 September, 2022)

  D Petrou, K Drouzas, O Tsotsorou, G Liapis, S Lionaki
• PO.8.175 Antimalarial drugs and electrocardiographic alterations in patients with systemic lupus erythematosus (27 September, 2022)

  C Riesco Barcena, S Leal Rodríguez, ME Acosta de la Vega, E Grau García, C Pávez Perales, AV Huaylla Quispe, M De la Rubia, P Muñoz Martínez, L Mas Sánchez, I Martínez Cordellat, C Nájera Herranz, R Negueroles Albuixech, F Ortiz-Sanjuán, E Vicens Bernabéu, I Cánovas Olmos, JJ Fragio Gil, L González Puig, J Oller Rodríguez, J Ivorra Cortés, JA Román Ivorra
• PO.8.176 Inflammation in blood and placenta in SLE pregnancies (27 September, 2022)

  M Stockfelt, A Torell, G Larsson, H Puttonen, D Leonard, L Rönnblom, M Saleh, C Sjöwall, H Strevens, J Andreas, AA Bengtsson, E Trysberg, M Majcuk Sennström, A Zickert, E Svenungsson, I Gunnarsson, K Christenson, J Bylund, B Jacobsson, A Rudin, A Lundell
• PO.8.177 Low complement levels in the first trimester predict disease flare in SLE pregnancy: a network meta-analysis on 532 patients (27 September, 2022)

  M Radin, F Crisafulli, I Cecchi, E Klumb, G De Jesùs, MA Saavedra, GV Reyes-Navarro, L Iaccarino, M Larosa, G Moroni, F Tamborini, D Roccatello, L Andreoli, C Chighizola, S Sciascia
• PO.8.179 Factors associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus (27 September, 2022)

  CI Sieiro Santos, C Moriano Morales, E Díez Álvarez
• PO.8.180 Biomarkers before conception related to adverse pregnancy outcomes in patients with systemic lupus erythematosus and primary sjögren’s syndrome: a retrospective cohort study (27 September, 2022)

  JJ Fierro, GM Verstappen, JR Prins, H Bootsma, J Westra, K De Leeuw
• PO.8.181 Lupus pregnancies: pooled data from sub-saharan Africa (27 September, 2022)

  M Essouma, JR Nkeck, JJ Bigna, GA Nkoro, S Ralandison, E Hachulla
• PO.8.182 Pregnancy outcome in saudi women with systemic lupus erythematosus (27 September, 2022)

  I Al-Homood, A Alserehi
• PO.8.183 Sle female patient presented with fatal cytophagic histiocytic panniculitis (27 September, 2022)

  M Shalaby, K Abd Al Hamid
• PO.8.184 Will there be a pattern of nailfold video-capillaroscopy in patients with systemic lupus erythematosus? (27 September, 2022)

  C Mazeda, S Silva, S Azevedo, A Barcelos
• PO.8.185 Microvascular changes in systemic lupus erythematosus and systemic sclerosis (27 September, 2022)

  C Mazeda, S Silva, S Azevedo, A Barcelos
• PO.8.186 SLE-T2T – a digital treat-to-target clinical decision support system for the management of systemic lupus erythematosus patients: development and usability evaluation (27 September, 2022)

  A Parra Sanchez, MG Grimberg, MMA Hanssen, MO Aben, EE Jairth, PS Dhoeme, M Tsang-A-Sjoe, A Voskuyl, JH Leopold, R Van Vollenhoven